RWMA Stock Overview Operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Rockwell Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Rockwell Medical Historical stock prices Current Share Price US$1.89 52 Week High US$4.56 52 Week Low US$1.12 Beta 1.39 1 Month Change -10.86% 3 Month Change -50.71% 1 Year Change 67.97% 3 Year Change -28.13% 5 Year Change -92.47% Change since IPO -98.03%
Recent News & Updates Rockwell Medical Promotes Jesse Neri to Chief Financial Officer Dec 12
Forecast breakeven date moved forward to 2024 Nov 15
Third quarter 2024 earnings released: EPS: US$0.053 (vs US$0.068 loss in 3Q 2023) Nov 13
Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 14
New major risk - Share price stability Sep 24
Second quarter 2024 earnings released: EPS: US$0.011 (vs US$0.20 loss in 2Q 2023) Aug 09 See more updates Rockwell Medical Promotes Jesse Neri to Chief Financial Officer Dec 12
Forecast breakeven date moved forward to 2024 Nov 15
Third quarter 2024 earnings released: EPS: US$0.053 (vs US$0.068 loss in 3Q 2023) Nov 13
Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 14
New major risk - Share price stability Sep 24
Second quarter 2024 earnings released: EPS: US$0.011 (vs US$0.20 loss in 2Q 2023) Aug 09 Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond
Rockwell Medical, Inc. Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities Aug 07
Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer May 30
New major risk - Financial position May 30
First quarter 2024 earnings released: US$0.059 loss per share (vs US$0.14 loss in 1Q 2023) May 15 Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024
Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024 Apr 17
Rockwell Medical, Inc., Annual General Meeting, May 21, 2024 Apr 16
Full year 2023 earnings released: US$0.36 loss per share (vs US$1.89 loss in FY 2022) Mar 21
Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Feb 09
Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023 Jan 08
New major risk - Financial position Nov 19
Third quarter 2023 earnings released: US$0.068 loss per share (vs US$0.40 loss in 3Q 2022) Nov 16
Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023 Nov 15 Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance
Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors Oct 18
Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Oct 17
Forecast to breakeven in 2025 Oct 06
Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer Sep 16 Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023
Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.56 loss in 2Q 2022) Aug 15
Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Jul 18
New major risk - Shareholder dilution Jul 13
Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million. Jul 12
First quarter 2023 earnings released: US$0.095 loss per share (vs US$0.84 loss in 1Q 2022) May 16
Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023 May 16
Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023 Feb 17
Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.89 loss in 3Q 2021) Nov 16
Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 15
Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Oct 18
Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer Sep 08
Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 04 Rockwell Medical, Inc. Provides Clinical Update Rockwell Medical, Inc. announced that it has received $14.9 million in funding Jun 04
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements Jun 02
Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial May 13
Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022 May 12
Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China Apr 26 Rockwell Medical, Inc. announced delayed annual 10-K filing Apr 03
Forecast to breakeven in 2023 Feb 15
Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion Dec 15
Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 3Q 2020) Nov 16
Forecast to breakeven in 2023 Sep 23
Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.099 loss in 2Q 2020) Aug 18
Rockwell Medical Receives Written Notice from the Nasdaq Stock Market Jun 19
First quarter 2021 earnings released: US$0.083 loss per share (vs US$0.12 loss in 1Q 2020) May 19
No longer forecast to breakeven May 19
Rockwell Medical, Inc. Announces Marketing Approval of Triferic® AVNU™ in Canada Apr 29
Full year 2020 earnings released: US$0.41 loss per share (vs US$0.56 loss in FY 2019) Apr 03
Rockwell Medical, Inc. to Report Q4, 2020 Results on Mar 31, 2021 Mar 19
Rockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis Feb 10
New 90-day high: €1.20 Feb 08
Rockwell Medical, Inc.(NasdaqGM:RMTI) dropped from S&P Healthcare Equipment Select Industry Index Jan 28
Rockwell Medical, Inc. Announces Termination of Ajay Gupta, M.D. as the Company’s Chief Scientific Officer Jan 26
New 90-day high: €1.05 Jan 21
Insider recently sold €84k worth of stock Dec 20
Rockwell Medical, Inc. Appoints Andrea Heslin Smiley to the Board as Class II Director and as Member of the Governance and Nominating Committee Dec 17
Revenue misses expectations Nov 12
Third quarter 2020 earnings released: US$0.10 loss per share Nov 12
Rockwell Medical, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 28
New 90-day low: €0.84 Oct 21
Rockwell Medical, Inc. Announces I.V. Triferic and Peritoneal Dialysis Study Abstracts Selected as Best-In-Category at the Annual Dialysis Conference Sep 29
New 90-day low: €0.93 Sep 26
Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate Platform Sep 26
New 90-day low - €1.31 Aug 21
First half earnings released Aug 11
New 90-day low - €1.47 Jul 30 Shareholder Returns RWMA DE Medical Equipment DE Market 7D -4.4% 3.6% 0.5% 1Y 68.0% -0.9% 15.3%
See full shareholder returns
Return vs Market: RWMA exceeded the German Market which returned 15.3% over the past year.
Price Volatility Is RWMA's price volatile compared to industry and market? RWMA volatility RWMA Average Weekly Movement 14.3% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: RWMA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RWMA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
Show more Rockwell Medical, Inc. Fundamentals Summary How do Rockwell Medical's earnings and revenue compare to its market cap? RWMA fundamental statistics Market cap €61.96m Earnings (TTM ) -€1.38m Revenue (TTM ) €95.77m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RWMA income statement (TTM ) Revenue US$98.92m Cost of Revenue US$82.19m Gross Profit US$16.72m Other Expenses US$18.15m Earnings -US$1.43m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.044 Gross Margin 16.91% Net Profit Margin -1.44% Debt/Equity Ratio 30.4%
How did RWMA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 03:37 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Rockwell Medical, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Jonathan Aschoff Brean Capital Ritu Baral Canaccord Genuity
Show 13 more analysts 
